Cargando…

Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose

Rivaroxaban, an oral anticoagulant, directly inhibits factor Xa (FXa). A 35-month-old boy was brought to the emergency department 15 minutes after ingesting 200 mg of rivaroxaban (16 mg/kg). Activated charcoal (AC) was administered; the patient was observed with monitoring of plasma anti-FXa levels...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carr, Brendan M., Roy, David J., Bangh, Stacey A., Hellmich, Thomas R., Walker, Laura E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	University of California Irvine, Department of Emergency Medicine publishing Western Journal of Emergency Medicine 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075494/ https://www.ncbi.nlm.nih.gov/pubmed/30083644 http://dx.doi.org/10.5811/cpcem.2018.5.38373

Ejemplares similares

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells
por: Sohma, Ryoichi, et al.
Publicado: (2023)

Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression
por: Ito, Yusuke, et al.
Publicado: (2021)

Should activated charcoal be given after tramadol overdose?
por: Khosrojerdi, Hamid, et al.
Publicado: (2013)

Management of Massive Rivaroxaban Overdose With Acetaminophen and Isosorbide Mononitrate Overdose
por: Casey, Bradley, et al.
Publicado: (2023)

The Role of Anti-Factor Xa Activity in the Management of Ecchymosis in Patients Receiving Rivaroxaban after Total Knee Arthroplasty
por: Wang, Han, et al.
Publicado: (2023)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation
por: Lucas, Fabienne, et al.
Publicado: (2021)

Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
por: Harenberg, Job, et al.
Publicado: (2011)

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation
por: Horinaka, Shigeo, et al.
Publicado: (2017)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme
por: Haas, Sylvia
Publicado: (2009)

Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice
por: Wu, Tao-Cheng, et al.
Publicado: (2015)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
por: Perzborn, E, et al.
Publicado: (2014)

Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
por: Anis, Takla R, et al.
Publicado: (2021)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
por: Riahi, Nada, et al.
Publicado: (2023)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis
por: Yentz, Sarah, et al.
Publicado: (2015)

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
por: Burghaus, Rolf, et al.
Publicado: (2014)

Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
por: Dah, Kingsley, et al.
Publicado: (2023)

The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin
por: Solayar, Gandhi N, et al.
Publicado: (2011)

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms
por: Whitman-Purves, Emily, et al.
Publicado: (2017)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
por: Meihandoest, Tamana, et al.
Publicado: (2022)

Conservative management of massive rivaroxaban overdose: A case report and literature review
por: Ghodsi, Alireza, et al.
Publicado: (2021)

Management of life-threatening calcium channel blocker overdose with continuous veno-venous hemodiafiltration with charcoal hemoperfusion
por: Garg, Suneel K., et al.
Publicado: (2014)

Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban
por: Zhou, Qianxing, et al.
Publicado: (2011)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Clinical Scenarios for Discordant Anti-Xa
por: Vera-Aguilera, Jesus, et al.
Publicado: (2016)

Determination of rivaroxaban in patient’s plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS)
por: Derogis, Priscilla Bento Matos, et al.
Publicado: (2017)

Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients
por: Brakta, Charlyne, et al.
Publicado: (2023)

Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 – The role of anti-Xa monitoring
por: Kofteridis, Diamantis P., et al.
Publicado: (2021)

Commentary: Comparison of activated charcoal and sodium polystyrene sulfonate resin efficiency on reduction of amitriptyline oral absorption in rat as treatments for overdose and toxicities
por: Michael, Youstina, et al.
Publicado: (2017)

Variability on the energy properties of charcoal and charcoal briquettes for barbecue
por: Mencarelli, A., et al.
Publicado: (2022)

On the Existence of Charcoal in the Lungs
por: Graham, Thomas
Publicado: (1834)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease‐Activated Receptor Pathway
por: Ichikawa, Hiroaki, et al.
Publicado: (2019)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tv0bnupsvugn2e5klq5duprduv